Published in J Psychiatry Neurosci on March 01, 2013
Antidepressant effects of botulinum toxin A: scientific rationale. J Psychiatry Neurosci (2013) 0.97
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res (2013) 0.82
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol (2016) 0.81
Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice. Toxins (Basel) (2015) 0.75
Antidepressant effects of botulinum toxin A: scientific rationale; author response. J Psychiatry Neurosci (2013) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry (2011) 3.62
Treatment non-adherence in affective disorders. Acta Psychiatr Scand (2002) 3.53
Autonomic nervous system activity distinguishes among emotions. Science (1983) 3.50
Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res (2010) 3.48
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74
Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA (2012) 2.40
Inhibiting and facilitating conditions of the human smile: a nonobtrusive test of the facial feedback hypothesis. J Pers Soc Psychol (1988) 2.29
Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol (2007) 2.22
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) (2006) 2.07
Rational regulation of learning dynamics by pupil-linked arousal systems. Nat Neurosci (2012) 1.99
Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res (2012) 1.90
Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci (2012) 1.90
Stress reduction correlates with structural changes in the amygdala. Soc Cogn Affect Neurosci (2009) 1.86
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 1.82
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol (2008) 1.60
Emotion and facial efference: a theory reclaimed. Science (1985) 1.58
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry (2010) 1.55
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci (2010) 1.36
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) (2011) 1.36
Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther (2011) 1.34
The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex (2008) 1.28
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (2011) 1.27
Cosmetic use of botulinum toxin-a affects processing of emotional language. Psychol Sci (2010) 1.22
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (2012) 1.21
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol (2010) 1.15
Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth (1981) 1.09
Cyloserine as an antidepressant agent. Am J Psychiatry (1959) 1.08
Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol (2011) 1.05
Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol (2009) 1.03
Prediction of psilocybin response in healthy volunteers. PLoS One (2012) 0.94
The effects of BOTOX injections on emotional experience. Emotion (2010) 0.94
Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A (2012) 0.81